Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Chlorogenic Acid Shields Against Bone Loss, Boosts Osteoblasts

ReachMD Healthcare Image

"[...] chlorogenic acid appears to be a promising candidate for the management of osteoporosis."

BUFFALO, NY- March 26, 2024 – A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 5, entitled, "Chlorogenic acid prevents ovariectomized-induced bone loss by facilitating osteoblast functions and suppressing osteoclast formation."

Osteoporosis is a common bone disease in aging populations, principally in postmenopausal women. Anti-resorptive and anabolic drugs have been applied to prevent and cure osteoporosis and are associated with different adverse effects. Du-Zhong is usually applied in Traditional Chinese Medicine to strengthen bone, regulate bone metabolism, and treat osteoporosis. Chlorogenic acid is a major polyphenol in Du-Zhong.

In this new study, researchers Chien-Yi Ho, Chih-Hsin Tang, Trung-Loc Ho, Wen-Ling Wang, and Chun-Hsu Yao from China Medical University, China Medical University Hospital and Asia University found chlorogenic acid to enhance osteoblast proliferation and differentiation. Chlorogenic acid also inhibited RANKL-induced osteoclastogenesis. Notably, ovariectomy significantly decreased bone volume and mechanical properties in the ovariectomized (OVX) rats. Administration of chlorogenic acid antagonized OVX-induced bone loss.

"Taken together, chlorogenic acid seems to be a hopeful molecule for the development of novel anti-osteoporosis treatment."

Read the full paper: DOI:

Corresponding Authors: Wen-Ling Wang, Chun-Hsu Yao

/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full



Facebook Comments

Schedule22 May 2024